A 4-year-old boy, diagnosed with leukemia, was enrolled in a clinical trial that used placenta-derived and umbilical cord blood stem cells. He is now in remission and enjoying life as a first-grader.
Americord Registry is pioneering new cord blood techniques, called CordAdvantage, that will provide more treatment options for a variety of patients, in the near future.
Americord's CordAdvantage service collects and stores placenta cord blood and may preserve many times more stem cells than can be obtained from umbilical cord blood alone.